Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nitric oxide and thromboxane A2-mediated pulmonary microvascular dysfunction.

J K Wright1, L T Kim, T E Rogers

  • 1Department of Surgery, University of Texas Southwestern Medical School and Dallas Veterans Affairs Medical Center 75235-0156, USA.

Archives of Surgery (Chicago, Ill. : 1960)
|March 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Comprehensive Evaluation of Job Rotation: Biomechanical Risk, Body Discomfort, and Psychosocial Demands.

Human factors·2026
Same author

Amelioration of transcriptional disturbances in female BACHD rats by environmental enrichment.

Experimental neurology·2025
Same author

Measurement of the Positive Muon Anomalous Magnetic Moment to 127 ppb.

Physical review letters·2025
Same author

The safety of deep sedation for uterine dilation and evacuation in medically complex patients: a retrospective analysis at an urban center (2018-2024).

International journal of obstetric anesthesia·2025
Same author

Dipole Moment of a Superatom.

Physical review letters·2024
Same author

Operando electron spin probes for the study of battery processes.

Journal of magnetic resonance (San Diego, Calif. : 1997)·2024

The lung releases nitric oxide (NO) to protect against thromboxane A2. This NO release helps counteract the inflammatory and blood vessel constricting effects of thromboxane A2.

Area of Science:

  • Pulmonary physiology
  • Vascular biology
  • Biochemistry

Background:

  • Thromboxane A2 (TXA2) is a potent mediator of inflammation and vasoconstriction.
  • The lung's response to TXA2 involves complex signaling pathways.
  • Nitric oxide (NO) is a key signaling molecule with vasodilatory and anti-inflammatory properties.

Purpose of the Study:

  • To investigate if the lung produces nitric oxide (NO) in response to thromboxane A2 (TXA2).
  • To determine if NO acts as a protective mechanism against the adverse effects of TXA2 in the lung.

Main Methods:

  • Isolated rat lungs were perfused with buffer containing either an NO synthase inhibitor (L-NAME), an NO donor (sodium nitroprusside), or buffer alone.
  • The TXA2 receptor agonist (U-46619) was administered to the lungs.

Related Experiment Videos

  • Measurements included capillary filtration coefficient, pulmonary arterial pressure, vascular resistance, and perfusate cyclic guanosine monophosphate (cGMP) levels.

    • Main Results:

    • U-46619 significantly increased lung capillary filtration coefficient, pulmonary arterial pressure, and vascular resistance.
    • Sodium nitroprusside attenuated the effects of U-46619 on capillary filtration coefficient and pulmonary arterial pressure.
    • L-NAME exacerbated the effects of U-46619 on pulmonary arterial pressure and vascular resistance.
    • U-46619 exposure led to a significant increase in perfusate cGMP levels, indicating NO release.

    Conclusions:

    • The lung releases nitric oxide (NO) in response to thromboxane A2 (TXA2).
    • NO release serves as a protective mechanism against the pro-inflammatory and vasoconstrictive actions of TXA2 in the lung.